These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22770610)

  • 41. Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).
    Mott BT; Tanega C; Shen M; Maloney DJ; Shinn P; Leister W; Marugan JJ; Inglese J; Austin CP; Misteli T; Auld DS; Thomas CJ
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6700-5. PubMed ID: 19837585
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Meridianin derivatives as potent Dyrk1A inhibitors and neuroprotective agents.
    Yadav RR; Sharma S; Joshi P; Wani A; Vishwakarma RA; Kumar A; Bharate SB
    Bioorg Med Chem Lett; 2015 Aug; 25(15):2948-52. PubMed ID: 26048785
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A link between MAP kinase and p34(cdc2)/cyclin B during oocyte maturation: p90(rsk) phosphorylates and inactivates the p34(cdc2) inhibitory kinase Myt1.
    Palmer A; Gavin AC; Nebreda AR
    EMBO J; 1998 Sep; 17(17):5037-47. PubMed ID: 9724639
    [TBL] [Abstract][Full Text] [Related]  

  • 44. QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors.
    Koo KA; Kim ND; Chon YS; Jung MS; Lee BJ; Kim JH; Song WJ
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2324-8. PubMed ID: 19282176
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Indazoles as potential c-Met inhibitors: design, synthesis and molecular docking studies.
    Ye L; Ou X; Tian Y; Yu B; Luo Y; Feng B; Lin H; Zhang J; Wu S
    Eur J Med Chem; 2013 Jul; 65():112-8. PubMed ID: 23702473
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation.
    Suárez RM; Chevot F; Cavagnino A; Saettel N; Radvanyi F; Piguel S; Bernard-Pierrot I; Stoven V; Legraverend M
    Eur J Med Chem; 2013 Mar; 61():2-25. PubMed ID: 22749189
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
    Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules.
    Rothweiler U; Stensen W; Brandsdal BO; Isaksson J; Leeson FA; Engh RA; Svendsen JS
    J Med Chem; 2016 Nov; 59(21):9814-9824. PubMed ID: 27736065
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Glycoglycerolipid analogues inhibit PKC translocation to the plasma membrane and downstream signaling pathways in PMA-treated fibroblasts and human glioblastoma cells, U87MG.
    Colombo D; Tringali C; Franchini L; Cirillo F; Venerando B
    Eur J Med Chem; 2011 May; 46(5):1827-34. PubMed ID: 21388717
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships.
    Ermoli A; Bargiotti A; Brasca MG; Ciavolella A; Colombo N; Fachin G; Isacchi A; Menichincheri M; Molinari A; Montagnoli A; Pillan A; Rainoldi S; Sirtori FR; Sola F; Thieffine S; Tibolla M; Valsasina B; Volpi D; Santocanale C; Vanotti E
    J Med Chem; 2009 Jul; 52(14):4380-90. PubMed ID: 19555113
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and evaluation of alkenyl indazoles as selective Aurora kinase inhibitors.
    Blanchard S; William AD; Lee AC; Poulsen A; Teo EL; Deng W; Tu N; Tan E; Goh KL; Ong WC; Ng CP; Goh KC; Bonday Z; Sun ET
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2443-7. PubMed ID: 20338758
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity.
    Islam I; Bryant J; Chou YL; Kochanny MJ; Lee W; Phillips GB; Yu H; Adler M; Whitlow M; Ho E; Lentz D; Polokoff MA; Subramanyam B; Wu JM; Zhu D; Feldman RI; Arnaiz DO
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3814-8. PubMed ID: 17531483
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis and quantum chemical studies of new 4-aminoquinazoline derivatives as Aurora A/B kinase inhibitors.
    Zheng M; Zheng Y; Xue Y; Liu Y; An L; Zhang L; Ji M; Xue B; Wu X; Gong X; Gu N; Zhan X
    Chem Biol Drug Des; 2013 Mar; 81(3):399-407. PubMed ID: 23279802
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKε kinases.
    Wang T; Block MA; Cowen S; Davies AM; Devereaux E; Gingipalli L; Johannes J; Larsen NA; Su Q; Tucker JA; Whitston D; Wu J; Zhang HJ; Zinda M; Chuaqui C
    Bioorg Med Chem Lett; 2012 Mar; 22(5):2063-9. PubMed ID: 22305584
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors.
    Jiao X; Kopecky DJ; Liu J; Liu J; Jaen JC; Cardozo MG; Sharma R; Walker N; Wesche H; Li S; Farrelly E; Xiao SH; Wang Z; Kayser F
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6212-7. PubMed ID: 22929232
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.
    Falke H; Chaikuad A; Becker A; Loaëc N; Lozach O; Abu Jhaisha S; Becker W; Jones PG; Preu L; Baumann K; Knapp S; Meijer L; Kunick C
    J Med Chem; 2015 Apr; 58(7):3131-43. PubMed ID: 25730262
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis of N,N'-bis(5-arylidene-4-oxo-3,5-dihydro-4H-imidazol-2-yl)diamines bearing various linkers and biological evaluation as potential inhibitors of kinases.
    Coulibaly WK; Paquin L; Bénie A; Bekro YA; Durieu E; Meijer L; Bazureau JP
    Eur J Med Chem; 2012 Dec; 58():581-90. PubMed ID: 23174317
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exploration of diverse hinge-binding scaffolds for selective Aurora kinase inhibitors.
    Ji Z; Dai Y; Abad-Zapatero C; Albert DH; Bouska JJ; Glaser KB; Marcotte PA; Soni NB; Magoc TJ; Stewart KD; Wei RQ; Davidsen SK; Michaelides MR
    Bioorg Med Chem Lett; 2012 Jul; 22(14):4528-31. PubMed ID: 22727637
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-beta type I receptor (ALK5) inhibitors.
    Ren JX; Li LL; Zou J; Yang L; Yang JL; Yang SY
    Eur J Med Chem; 2009 Nov; 44(11):4259-65. PubMed ID: 19640613
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Covalent inhibitors of interleukin-2 inducible T cell kinase (itk) with nanomolar potency in a whole-blood assay.
    Zapf CW; Gerstenberger BS; Xing L; Limburg DC; Anderson DR; Caspers N; Han S; Aulabaugh A; Kurumbail R; Shakya S; Li X; Spaulding V; Czerwinski RM; Seth N; Medley QG
    J Med Chem; 2012 Nov; 55(22):10047-63. PubMed ID: 23098091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.